1197 related articles for article (PubMed ID: 18774869)
1. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
6. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
[TBL] [Abstract][Full Text] [Related]
7. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
8. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
15. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Chue PS; Heeg B; Buskens E; van Hout BA
Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
[TBL] [Abstract][Full Text] [Related]
16. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.
Quintero J; Oyagüez I; González B; Cuervo-Arango I; García I; Casado MA
Clin Drug Investig; 2016 Jun; 36(6):479-90. PubMed ID: 27000061
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.
Frey S; Linder R; Juckel G; Stargardt T
Eur J Health Econ; 2014 Mar; 15(2):133-42. PubMed ID: 23420082
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Olivares JM; Rodriguez-Morales A; Diels J; Povey M; Jacobs A; Zhao Z; Lam A; Villalobos Vega JC; Cuéllar JA; de Castro FJ; Quintero CM; Martíin JF; Domínguez P; Ojeda JL; Cortés SS; Cala FI; Marín CG; Castro LM; Duaso MA; Albarracín JR; Vergara GN; Benítez AF; Cleries FM; Pérez-Brian JM; Aragón AB; Navarro JC; Biedma JA; de Pedro RB; González JF; López ME; Moreno HD; López JA; Rodríguez EO; de Hoyos CM; Sacristán MP; Martín MD; Ballesteros EM; Rodríguez PA; Menéndez LF; Rivas RS; del Pino Cuadrado P; Lauffer JC; Solano JJ; Martínez JM; Solano FG; Rodríguez PG; Rodríguez JA; Cano TR; Fortacin MD; Lobeiras JM; Sampedro JM; Bravo AP; Pellicer AF; López MD; Liste JF; Fernández MR; Losada AC; Mendez RV; Romero SA; Blanco JJ; Bonaselt IT; Mahia MC; del Valle EF; Yañez PQ; Camarasa MG; Alonso JA; Mendez GF; Feliz FD; Lamela MA; Piñero MV; Alvarado PF; Gómez IL; Martín PF; Gómez JL; López AG; Jiménez AR; Nafs AE; Barquero NC; Ortiz RF; Noguera JL; Carrasco PR; Muñoz JM; Palma MM; Hortelano CM; Bonome LS; Sevilla JS; Juan JM; Ramos JM; Muñoz JL; Guisasola JE; Vazquez LS; Guerras FC; Nebot FJ; Fernández FJ; Nicolau AL; Subirats RC; Kidias MM; Navarro VF; García BF; del Rosal FM; de Vicente Muñoz T; Ballester JA; Lieb PM; Martel AD; Bea ER; Joaquim IG; Enjuanes FB; Piñol MB; Carbonell EF; Muñoz RM; Giribets CA; Sans LA; Blanco AS; Felipe MA; Muñoz PG; Villanueva AP; Arroyo MB; Borri RC; Fallada SM; Merola MC; Rodon EP; Palmes JR; Martínez EP; Catala JM; Coca AS; Ferrandiz FP; Paya EF; Caballero GI; Bonet AF; Figueras JF; Pagador PM; Garibo MM; Camo VP; Carrillo CS; Valero CP; Rebollo FJ; García Campayo J; Sala Ayma JM; Roig MM; de Uña Mateos MA; Bertolin RG; García AM; Mazo FJ; Velasco JL; Pérez LS; Casado CJ; Barba JJ; Diaz MC; Rubio JP; Mandoli AS; Herrero AU; Martínez AR; Serrano PS; Rodríguez EN; Montesinos JS; Macia JF; Mateos Marcos AM; Soto JV; Dumont MV; Pagan JP; Martínez VB; Santiuste de Pablos M; Delgado CE; Quiles MD; López FJ; Navarro PP; Torres AM; Ingles FJ; Arias-Camison JM; Manzano JC; Peña RV; Guitarte GP; Fontecilla HB; Romero JB; Gil RS; Lozano JM; Adanez LD; Zarranz Herrera-Oria I; Jiménez JP; Vaz FC; García OS; Anton CC; Casula RR; Hernandez MC; Escabias FT; Torresano JR; Pérez-Villamil AH; Estevez L; Figuero MA; Muñoz de Morales A; Calvin JL; Criado MD; Rodríguez VM; Ambrosolio EB; Madera PM; Alfaro GP; Vidal MM; Valtuille AG; Ruiz O; Cabornero GL; Echevarria Martínez de Bujo M; Mallen MJ; Puigros JS; Martorell AL; Forteza AC; Arrebola ER; Rodríguez de la Torre M; Saiz CG; Bardolet I Casas C; Linde ER; De Arce Cordon R; Molina EM; Carazo FJ; Romero JJ; Cano DV; Dorado MS; Velazquez SC; Sánchez AJ; Leon SO; Sánchez KP; Benitez MH; Zugarramurai AI; Contreras MA; De la Varga González M; Marín PB; Robina FG; García MS; Pérez FJ; Bros PC; Gómez AC; de Dios Molina Martín J; Perera JL; Averbach MC; Perera JL; Palancares EG; Gallego de Dios MT; Rojo CF; Iglesias SS; Merino MI; Mestre NP; Urdaniz AP; Sánchez JM; Seco RG; Muñoz JF; Agut MM; Lozano ML; Herguedas FM; Pena AT; García JV; Martínez AV; Sanz Granado OS; Fernández MA; Canseco JM; López PA; Martín MA; Barrio JA; Ubago JG; Bennassar MR; Díez JM; Fleta JL; Fortes FP; López CA; Medina O; Alvarez DF; Roca JM; Valladolid GR; Tavera JA; García-Castrillon Sales JA; Llordes IB; Melgarejo CA; Cañas de la Paz F; Callol VV; García MB; García JB; Leal FJ; Corrales EC; Iglesias ES; Gómez MA; Serrano GG; Chillarón EG; Aguado FJ; Castillo JJ; González AG; Vázquez JG; Peralvarez MB; Diaz MR; Mesa MY; Artiles FJ; Chao MA; Mesa MY; del Rosario Santana P; Escudero MA; Berenguer MM; Llacer JM; Berna JA; Ortiz JB; Pardell LT; Hernández-Alvarez de Sotomayor C; Méndez MR; Garate RC; Múgica BD; González MC; Domingo JP; Navarro CS; Vera GS; Cuquerella MA; Monzo JL; Boada PC; Pérez MF; Parrado EC; Sánchez JJ; Fernández JC;
Eur Psychiatry; 2009 Jun; 24(5):287-96. PubMed ID: 19195847
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
20. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.
Su KP; Chang HC; Tsai SJ; Yen FC; Tang CH
Value Health; 2009; 12 Suppl 3():S118-21. PubMed ID: 20586973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
